EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
AstraZeneca revealed on Tuesday, Dec. 26, that it will buy the China-based biopharmaceutical company Gracell Biotechnologies for up to $1.2 billion. The Anglo-Swedish multinational pharma and biotechnology firm is making this move to achieve its cell therapy ambitions.
According to Reuters, AstraZeneca is also aiming to use the acquisition of Gracell Biotechnologies to boost its presence in China, which is currently the second-largest pharmaceutical market in the world, further.
Payment Terms and Other Acquisition Arrangements
AstraZeneca and Gracell agreed to an all-cash deal for the acquisition. Once the buyout is completed, the former’s portfolio is set to expand with the addition of several experimental therapies.
AstraZeneca is buying the Chinese firm at $2 per ordinary share. This is also equivalent to $10 per American Depository Share of Gracell, which represents a premium of 61.6% based on its Dec. 22 closing.
Merging of Expertise to Achieve Growth and New Biotech Innovation
AstraZeneca and Gracell are looking to combine their respective expertise and resources to develop effective therapies for diseases. They also expect to find new ways of optimizing the therapeutic profile of engineered T cells and take the lead in the next generation of autologous cell therapies.
“The proposed acquisition of Gracell will complement AstraZeneca’s existing capabilities and previous investments in cell therapy, where we have established our presence in CAR-T and T-cell receptor therapies (TCR-Ts) in solid tumors,” AstraZeneca’s executive vice president of Oncology research and development, Susan Galbraith, said in a press release.
She further explained, “GC012F will accelerate our cell therapy strategy in hematology with the opportunity to bring a potential best-in-class treatment to patients living with blood cancers using a differentiated manufacturing process, as well as exploring the potential for cell therapy to reset the immune response in autoimmune diseases.”
Gracell Biotechnologies’ founder, chairman, and chief executive officer, Dr. William Cao, also commented, “We look forward to working with AstraZeneca to accelerate our shared goal of bringing transformative cell therapies to more patients living with debilitating diseases.”
Photo by: Declan Sun/Unsplash
